Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables declines year over year

Q3 FY2026 accounts receivables of $29.5M (cash outflow) fell 25.5% year over year, behind the -14.2% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -10.4% a year.

Context

  • Accounts receivables amounted to 2.8% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -25.5% toward the trailing-twelve-month pace of -14.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$29.5M-298.8% QoQ
Last fiscal yearDec 2025
$26.13M+367.4% YoY
LTMSep 2026
-$63.73M-14.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.5%——
1 year+367.4%——
3-year CAGR-10.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
26.13M USD
Year-over-year change
+367.4%
4-year CAGR
+50.8%

Accounts Receivables vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's LTM Sep 2026 accounts receivables of $63.73M is the 6th largest of the 9 companies compared; the peer median is $33.22M.
  • Its year-over-year change of -14.2% is the 6th highest of 9, against a peer median of +90.7%.
  • Accounts receivables amounts to 6.6% of revenue for IONS, versus a peer median of 5.1%.
IONS Competitors Peer median
Accounts Receivables for IONS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$60.56B +173755.7%+40.6%5.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$357.64M +48.4%+99.1%7.4%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$264.55M +194.3%—12.1%
BIIBBiogen Inc.LTM Jun 2026$208.4M +578.8%—2.1%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$177.62M +133.1%—24.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$63.73M -14.2%-10.4%6.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$44.38M -720.6%-40.6%4.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$22.06M -1708.0%+37.0%3.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$1.37M -94.7%-18.2%2.1%
Peer median (excluding IONS) $33.22M+90.7%+37.0%5.1%

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.6M)(269.72M)(366.29M)(453.9M)(381.39M)
Depreciation & Amortization19.56M22.11M22.5M21.99M22.69M
Deferred Income Tax25.31M0000
Stock-Based Compensation120.68M100.26M105.81M130.2M133.87M
Change in Working Capital(113.82M)7.57M(77.26M)(209.39M)(51.22M)
Accounts Receivables5.05M36.36M(72.06M)5.59M26.13M
Inventory(2.84M)2.77M(6.39M)(5.07M)(13.67M)
Accounts Payables(6M)1.09M8.12M15.99M(15.36M)
Other Working Capital(110.03M)(32.65M)(6.93M)(225.9M)(48.31M)
Other Non-Cash Items7.67M(134.59M)7.73M10.15M7.45M
Operating Cash Flow30.8M(274.37M)(307.51M)(500.95M)(268.58M)
Capital Expenditures(17.9M)(20.1M)(28.01M)(45.28M)(51.44M)
Acquisitions (Net)5.95M254.08M22K00
Purchases of Investments(1.13B)(1.49B)(1.77B)(1.85B)(1.92B)
Sales of Investments1.34B989.15M1.58B1.77B1.7B
Other Investing Activities(5.95M)0(4.21M)(5.06M)(5.64M)
Investing Cash Flow194.91M(262.64M)(214.13M)(134.03M)(277.78M)
Debt Repayment313.57M(50.69M)86.9M(44.67M)483.24M
Common Stock Issued85.71M6.37M49.44M522.73M192.6M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(153.35M)(10.98M)507.74M00
Financing Cash Flow245.93M(55.3M)644.08M478.06M675.84M
Effect of Forex Changes(111K)(418K)352K(273K)702K
Net Change in Cash471.53M(592.72M)122.79M(157.19M)130.18M
Free Cash Flow12.9M(294.47M)(335.52M)(546.23M)(320.03M)

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.